Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,563,111
  • Shares Outstanding, K 83,768
  • Annual Sales, $ 0 K
  • Annual Income, $ -62,290 K
  • EBIT $ -39 M
  • EBITDA $ -40 M
  • 60-Month Beta 0.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 19.48

Options Overview Details

View History
  • Implied Volatility 80.06% (+0.02%)
  • Historical Volatility 292.31%
  • IV Percentile 6%
  • IV Rank 1.56%
  • IV High 320.47% on 04/10/25
  • IV Low 76.25% on 01/23/26
  • Expected Move (DTE 5) 1.19 (6.38%)
  • Put/Call Vol Ratio 0.60
  • Today's Volume 584
  • Volume Avg (30-Day) 5,365
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 60,646
  • Open Int (30-Day) 51,730
  • Expected Range 17.47 to 19.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.14
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.45 +189.08%
on 01/14/26
26.95 -30.76%
on 01/23/26
+12.16 (+187.08%)
since 01/13/26
3-Month
6.39 +192.02%
on 01/12/26
26.95 -30.76%
on 01/23/26
+10.66 (+133.25%)
since 11/13/25
52-Week
2.54 +634.65%
on 04/09/25
26.95 -30.76%
on 01/23/26
+13.74 (+279.27%)
since 02/13/25

Most Recent Stories

More News
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

Three standout stocks for 2026 have already generated massive returns of 56% or more this year, although they may cater to investors with a tolerance for risk.

CRVS : 18.66 (-0.53%)
USAR : 19.40 (+1.65%)
NUAI : 4.92 (+6.96%)
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten...

CRVS : 18.66 (-0.53%)
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten...

CRVS : 18.66 (-0.53%)
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten...

CRVS : 18.66 (-0.53%)
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment  75% of soquelitinib patients achieved EASI 75, 25%...

CRVS : 18.66 (-0.53%)
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and...

CRVS : 18.66 (-0.53%)
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results...

CRVS : 18.66 (-0.53%)
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing...

CRVS : 18.66 (-0.53%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 18.66 (-0.53%)
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic...

CRVS : 18.66 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 20.95
2nd Resistance Point 20.47
1st Resistance Point 19.56
Last Price 18.66
1st Support Level 18.17
2nd Support Level 17.69
3rd Support Level 16.78

See More

52-Week High 26.95
Last Price 18.66
Fibonacci 61.8% 17.63
Fibonacci 50% 14.75
Fibonacci 38.2% 11.86
52-Week Low 2.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar